Abstract: Mycobacterium tuberculosis, the causative agent of tuberculosis is quiet difficult to treat or say, recovery the patients is prolonged.Iraq has a high burden of Tuberculosis (TB) and ranks the 44th.worldwide among the countries with a high TB burden and the 5th.among the countries of the Eastern mediterranean Region.This study was designed to evaluate the Anti-tuberculosis effect of a new compound of Argan Oil 100%,which has been fetched from Morocco Kingdom combined with Sidr extract 62.5g\L against Mycobacterium tuberculosis. Ten isolates Mycobacterium tuberculosis were isolated from patients who attended Consultants Clinic of Respiratory and Thoracic Diseases in Hilla city, Iraq. All investigated patients were preliminary diagnosed by X- ray to have TB. The effect of mixture of Argan oil 100% and sidr extract 62.5g\L was tested on M. tuberculosis by incorporation the mixture with Lowenstein-Jensen (L.J) medium in different ratio to get final volume mixture: L.J. medium. Accordingly ratios were; 1: 9, 0.75:9.25, 0.5: 9.5, 0.4:9.6, 0.3:9.7, 0.25:9.75, 0.2:9.8 and 0.1: 9.9ml. L.J. medium was autoclaved for sterilization and kept to cool at 45C° then the appropriate concentrations the compound were added. The medium was inoculated with the TB.The growth of TBwas observed in positive control tube while no growth was seen in the tubes containing the mixture of compounds although the reading of TB. growth continued for28 days of incubation. Similar results displayed for all other mixtures of different ratio (1: 9, 0.75:9.25, 0.5: 9.5, 0.4:9.6, 0.3:9.7, 0.25:9.75, 0.2:9.8 and 0.1: 9.9)ml.The new compound used in this study revealed valuable effect against TB. Afterincorporated with culture media.
Keywords: Argan oil.Sidr extract.Anti-tuberculosis
[1]. RBrosch, SV.Gordon,A.Pym,K.Eiglmeier,T. Garnier, andS.T. Cole, Comparative genomics of the mycobacteria. Int J MedMicrobiol; 290(2), 2000, 143-152.
[2]. S.Mostowy, D. Cousins, J. Brinkman, A.Aranaz, and M.A. Behr, Genomic deletions suggest a phylogeny for the Mycobacteriumtuberculosis complex. J Infect Dis; 186(1), 2002, 74-80.
[3]. N.W.Schluger, The pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. Am J Respir Cell MolBiol; 32(4), 2005, 251-256.
[4]. C.J.Gallant,S. Malik,N.Jabado,M .Cellier,L.Simkin,B. B.Finlay, E. A.Graviss,P.Gros,J. M .Musser, and E.Schurr, Reduced in vitro functional activity of human NRAMP1 (SLC11A1) allele that predisposes to increasedrisk of pediatric tuberculosis disease, Genes Immun. 8(8), 2007, 691-8.
[5]. A.Wright, M.Zignol, andA. Van Deun, Epidemiology and ant tuberculosis drug resistance 2002-2007: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance,Lancet 373, 2009, 1861-1873.